Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

IDXX - IDEXX Laboratories, Inc. So'nggi... | Finranks

Home

/

IDXX

I

IDEXX Laboratories, Inc. (IDXX)

NMS – Real vaqt narxi. Valyuta: USD

570.69

-15.95 (-2.72%)

Bozor ochiq: Aug 12, 2026, 1:52 PM EDT

586.65

+0.01 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:49 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.

IDEXX Laboratories: Worth The Premium

IDEXX Laboratories: Worth The Premium

IDEXX Laboratories remains a buy, supported by a durable moat, strong recurring revenue, and a long-term international growth runway. Recent Q2 2026 results showed 9% organic revenue growth, EPS guidance raised to $14.69–14.94, and robust expansion of diagnostic offerings. Installed base growth for core machines is moderating in the US but remains early-stage internationally, underpinning multi-decade expansion potential.

Here is Why Growth Investors Should Buy Idexx (IDXX) Now

Here is Why Growth Investors Should Buy Idexx (IDXX) Now

Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.

IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market

IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market

IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.

IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript

IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript

IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript

IDEXX Laboratories Q2 Earnings Call Highlights

IDEXX Laboratories Q2 Earnings Call Highlights

IDEXX Laboratories NASDAQ: IDXX reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing strong recurring diagnostics revenue, product-cost benefits and continued momentum from new product introductions.

Videolar

No Data

There is no data to display

Press-relizlar

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.

IDEXX Laboratories Announces Second Quarter Results

IDEXX Laboratories Announces Second Quarter Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. Second Quarter Results The Company reports revenues of $1,217 million for the second quarter of 2026, an increase of 10% as reported and 9% organic, driven by Companion Animal Group ("CAG") growth of 9% as reported and organic, Water revenue growth of 15% as reported and 13% organic, and LPD revenue growth of 11% as reported and 9% org.